Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

289.50 -11.14 (-3.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 222,274
Open 301.52
Bid (Size) 289.00 (1)
Ask (Size) 292.50 (1)
Prev. Close 300.64
Today's Range 288.92 - 303.44
52wk Range 52.33 - 315.45
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Top Healthcare Stocks to Buy for January
These healthcare stocks have a lot going for them in the new year. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years
 
Via Benzinga

Performance

YTD
+1.43%
+1.43%
1 Month
+6.89%
+6.89%
3 Month
+294.09%
+294.09%
6 Month
+360.84%
+360.84%
1 Year
+417.98%
+417.98%

More News

Read More
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
Why These 7 Healthcare Stocks Could Soar in 2023
Via InvestorPlace
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today
Via Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
Via Benzinga
5 Top Stocks for January
Via The Motley Fool
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Via Benzinga
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
Via The Motley Fool
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
Via Investor's Business Daily
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
Via Benzinga
Why Madrigal Pharmaceuticals Was a Top Stock This Week
Via The Motley Fool
7 Drug Stocks That Will Soar in 2023
Via InvestorPlace
Earnings Optimism Puts Wind In Wall Street's Sails
Via Talk Markets
Why Did Viking Therapeutics Stock Skyrocket
Via MarketBeat
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
Via Benzinga
Peering Into Madrigal Pharmaceuticals's Recent Short Interest
Via Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Here's How An Options Trader Made $5.5 Million In One Day
Via Benzinga
Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
Via Talk Markets
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
Via Spotlight Growth
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.